Antigua and Barbuda vs High income: Immunization, Hib3
Immunization, Hib3 over time
- Antigua and Barbuda
- High income
How they compare
Antigua and Barbuda currently reports 99.0% against 93.2% in High income, a difference of 5.8%.
That makes Antigua and Barbuda's figure about 1.1 times High income's.
Across all 24 years both countries report, Antigua and Barbuda has been ahead every year.
Antigua and Barbuda ranks 1st and High income ranks 4th of 191 countries.
Antigua and Barbuda has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Antigua and Barbuda | High income | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 97.3% | 69.0% | 28.3% | Antigua and Barbuda |
| 2010s | 97.3% | 80.7% | 16.6% | Antigua and Barbuda |
| 2020s | 97.4% | 89.1% | 8.3% | Antigua and Barbuda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Antigua and Barbuda or High income?
- Antigua and Barbuda, at 99.0% against 93.2% in High income as of 2024.
- What is the difference in immunization, hib3 between Antigua and Barbuda and High income?
- 5.8%, with Antigua and Barbuda ahead.
- How many years of comparable data are there for Antigua and Barbuda and High income?
- 24 years are reported by both, from 2001 to 2024.
- How do Antigua and Barbuda and High income rank globally for immunization, hib3?
- Antigua and Barbuda ranks 1st and High income ranks 4th of 191 countries.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.